KZR vs ABBV vs JPM

For growth investors, AbbVie Inc.

(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate AbbVie Inc. (ABBV) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus AbbVie Inc. at 96. 1x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +123. 7%, compared to -98. 7% for Kezar Life Sciences, Inc. (KZR). Over 10 years, the gap is even starker: JPM returned +465. 8% versus KZR's -99. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 593% more volatile than ABBV relative to the S&P 500. On balance sheet safety, Kezar Life Sciences, Inc. (KZR) carries a lower debt/equity ratio of 3% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbbVie Inc.

(ABBV) is pulling ahead at 8. 6% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 1. 5% year-over-year, compared to -566. 1% for Kezar Life Sciences, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 0. 0% for Kezar Life Sciences, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus 0. 0% for KZR. At the gross margin level — before operating expenses — ABBV leads at 70. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 4x forward P/E versus 16. 0x for AbbVie Inc. — 1. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABBV: 12. 8% to $256. 92.

In this comparison, ABBV (2.

9% yield), JPM (1. 9% yield) pay a dividend. KZR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). Both have compounded well over 10 years (ABBV: +362. 2%, KZR: -99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (KZR (Healthcare) and ABBV (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: KZR is a small-cap quality compounder stock; ABBV is a large-cap quality compounder stock; JPM is a large-cap deep-value stock. ABBV, JPM pay a dividend while KZR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.